Research programme: viral therapeutics - Genekam

Drug Profile

Research programme: viral therapeutics - Genekam

Alternative Names: Zika virus therapeutics

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Genekam Biotechnology
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Ebola virus infections; Flavivirus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Zika virus infection

Most Recent Events

  • 19 Aug 2016 Early research in Middle East respiratory syndrome coronavirus in Germany (unspecified route)
  • 19 Aug 2016 Early research in Influenza virus infections in Germany (unspecified route)
  • 19 Aug 2016 Early research in Flavivirus infections in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top